comprehensive -WSS

comprehensive

author：comprehensive 2025-09-06 03:32:45 - browse：32783

Alex Hogan/STAT

SAN FRANCISCO — It seemed like there was a point during last year’s J.P. Morgan Healthcare Conference when we all collectively realized, “Oh, 2023 is going to be another slog.” Indeed, a downturn has weighed on the biotech industry for nearly three years.

But this January, things feel different. Maybe it’s the abundance of sunlight that filled San Francisco this week. More likely, it’s the surge of deals that came in December. Whatever the reason, sentiment around Union Square in recent days was markedly more positive this year.

Most everyone I spoke to this week noticed the change in tenor. “I’m feeling a lot of good energy, honestly,” Mira Chaurushiya, senior partner at VC Westlake Village BioPartners, told me Tuesday. “It’s not only what happened the last few weeks of the year, but what people are projecting moving forward.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Anesthesiologist group: stop taking Ozempic before surgery

leisure time

hotspot

WSS

The high cost of giving birth even with insurance

Duchenne breakthrough therapy leaves behind pioneering families

Continuity nursing helped my family in our darkest PICU moments

Malaria cases in Florida and Texas: Here’s what you need to know

Moonlake's readout produced a cash windfall. Risks remain

Maui's cultural, historic landmarks damaged in the devastating wildfires

focus

comprehensive

knowledge

BioMarin wins approval for gene therapy to treat hemophilia A

Anesthesiologist group: stop taking Ozempic before surgery

Psychedelics group wrestles with new pharma identity

How to save PrEP access — and even expand it

Apple is now the first public company to be valued at $3 trillion

For Cytokinetics, FDA rejection of heart drug would help, not hinder

Affirmative action in medical school literally saved lives

Twitch streamer Kai Cenat speaks out for 1st time since causing mayhem with Union Square giveaway

Drug repurposing or repositioning? The language matters

Heart attack and stroke risk calculators need revising

focus

Drastic changes should bring profitability, startup health insurers say

23andMe had bad news about my health. I wish a person had delivered it

Wegovy’s successful heart trial raises vital question about weight loss

Anavex keeps shifting the goalposts in its clinical trials

Methadone doses haven’t kept up in the age of fentanyl

For Cytokinetics, FDA rejection of heart drug would help, not hinder

leisure time

leisure time

hotspot

hotspot